
News|Articles|May 1, 2002
Revised rofecoxib labeling adds GI safety benefit, cardiovascular risk
Merck has issued revised labeling for its COX-2 inhibitor rofecoxib (Vioxx) that incorporate findings from the 8,000-patient VIGOR (Vioxx Gastrointestinal Outcomes Research) study.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
2
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
3
Quadruplet treatments for multiple myeloma are rising but access varies | ASH 2025
4
AstraZeneca’s Imfinzi gains landmark FDA approval for early gastric and gastroesophageal cancers
5






















































